Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for Macular Edema in RVO Following Anti-VEGF
NCT01449682Phase 3Completed
- Sponsor
- Retina Macula Institute
- Start
- Oct 2011
- Primary completion
- Jul 2012
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ozurdex in macular edema and retinal vein occlusion (RVO) (2 arms), sponsored by Retina Macula Institute. Primary endpoints: Macular Function Using Microperimetry at 48 weeks and Macular Function Using Multi-focal ERG at 48 weeks. Started Oct 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT01449682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449682.